Pharmaceutical opinion : **Interaction between statins and anti-HCVs**

Patient : \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ DOB \_\_\_\_\_/\_\_\_\_\_/\_\_\_\_\_ Telephone : \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

After analyzing your patient's file, I noticed a problem with his medication.

**Glecaprevir/Pibrentasvir (Maviret)**  and Simvastatin (Zocor)

**Interaction mechanism :** An increase in statins adverse effects may occur following co-administration with the anti-HCV drugs mentioned above. Statins are substrates of the hepatic P-gp, OATP1B1/1B3 and/or BCRP transporters that are inhibited by anti-HCVs.

***Glecaprevir/Pibrentasvir (Maviret) and Simvastatin***

Additional information:

• Glecaprévir/Pibrentasvir (Maviret) + Simvastatin 5 mg die: Simvastatin AUC ↑ 2.3-fold. The product monograph recommends avoiding this association.

Possible therapeutic options (Lovastatin/Simvastatin):

**\* The combination of Glecaprevir/Pibrentasvir (Maviret) and Simvastatin is contraindicated according to the product monograph. \***

* Suspend Simvastatin during hepatitis C treatment
\*From \_\_\_\_\_\_\_\_\_\_\_\_\_ to \_\_\_\_\_\_\_\_\_\_\_\_\_\_ \*
* Substitute Simvastatin for \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ REN : \_\_\_\_\_\_\_

* Other :\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ REN : \_\_\_\_\_\_\_

**Follow-up :** Adverse effects associated with lipid-lowering drugs: GI effects, myopathies (muscle fatigue/weakness, myalgia, muscle cramps) and rhabdomyolysis leading to renal failure.

Do not hesitate to contact us for additional information.
In collaboration,

Pharmacist : \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Telephone : \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_​ Fax : \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

As a prescription, date and sign:

Date : \_\_\_\_\_/\_\_\_\_\_/\_\_\_\_\_ Signature and licence : \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_